NMDA Receptor Antagonists Increase the Release of GLP-1 From Gut Endocrine Cells

Type 2 diabetes mellitus (T2DM) remains one of the most pressing health issues facing modern society. Several antidiabetic drugs are currently in clinical use to treat hyperglycaemia, but there is a need for new treatments that effectively restore pancreatic islet function in patients. Recent studie...

Descripció completa

Dades bibliogràfiques

Autors principals:	Malgorzata Cyranka, Thomas Monfeuga, Natascia Vedovato, Chelsea M Larabee, Anandhakumar Chandran, Enrique M Toledo, Heidi de Wet
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2022-04-01
Col·lecció:	Frontiers in Pharmacology
Matèries:	NMDA receptor (NMDAR) Glucagon-like peptide 1 (GLP-1) GLUTag cells MK-801 (dizocilpine) dextromethorphan (DMO), NMDA receptor antagonist
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fphar.2022.861311/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!